Global pharma major Lupin Limited (Lupin) announced the launch of United Food and Drug Administration (FDA) approved bumetanide injection USP, 1 mg/4 mL (0.25 mg/mL) single-dose vials and 2.5 mg/10 mL ...

Lupin’s average revenue will potentially increase 9.2 per cent Y-o-Y to Rs 5,502 crore as against Rs 5,038 crore in Q2FY24.

Drugmaker Lupin aims to be part of the first wave of generic drugmakers to make GLP-1 receptor agonists products, used to ...

Some buzzing pharma stocks including Cipla Ltd, Glenmark Pharmaceuticals Ltd and Lupin Ltd are likely to remain under the ...

Indian generic drugmaker Lupin reported a bigger-than-expected rise in second-quarter profit on Thursday, driven by strong demand for its respiratory and diabetes management drugs.

Global pharma major Lupin Limited on Friday announced that it has received tentative approval from the United States Food and ...

Macquarie analysts described the results as an "all-round beat". Although revenue aligned closely with their forecast, Ebitda ...

The company posted a net profit of Rs 852.6 crore in the quarter ended September in comparison to Rs 489.7 crore in the ...

October saw subdued growth in the Indian pharmaceutical market (IPM), with growth remaining in the low single digits, mainly ...

Lupin Limited delivered a strong financial performance for the second quarter, surpassing market expectations. Net profit for ...

Shares of the Lupin Ltd. traded at Rs 2095.25 on BSE at 11:10AM ... The stock commands a market value of Rs 95477.64 crore ...